title: The alternative CD20 transcript variant is not a surrogate marker for resistance to rituximab in patients with rheumatoid arthritis.
authors.affiliation: INSERM, Etablissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, UMR1098, Besançon.
authors.forename: Clémentine
authors.initials: C
authors.lastname: Gamonet
authors.affiliation: INSERM, Etablissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, UMR1098, Besançon.
authors.forename: Marina
authors.initials: M
authors.lastname: Deschamps
authors.affiliation: INSERM U987, University Versailles Saint Quentin, Simone Veil Department of Health Science, Chronic Inflammation and Immune System, LabEX InflameX, Montigny le Bretonneux.
authors.forename: Sandrine
authors.initials: S
authors.lastname: Marion
authors.affiliation: CHRU Besançon, Virologie, Université de Franche Comté, UPRES EA 4266 Agents Pathogènes et Inflammation, Besançon.
authors.forename: Georges
authors.initials: G
authors.lastname: Herbein
authors.affiliation: INSERM U987, University Versailles Saint Quentin, Simone Veil Department of Health Science, Chronic Inflammation and Immune System, LabEX InflameX, Montigny le Bretonneux.
authors.forename: Gilles
authors.initials: G
authors.lastname: Chiocchia
authors.affiliation: INSERM, UMR1097, Université Aux Marseille, Marseille.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Auger
authors.affiliation: INSERM, Etablissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, UMR1098, Besançon, Etablissement Français du Sang, Plateforme de Biomonitoring, LabEX LipSTIC, INSERM, CIC 1431, Centre investigation Clinique Biothérapie.
authors.forename: Philippe
authors.initials: P
authors.lastname: Saas
authors.affiliation: INSERM, Etablissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, UMR1098, Besançon, Etablissement Français du Sang, Plateforme de Biomonitoring, LabEX LipSTIC.
authors.forename: Christophe
authors.initials: C
authors.lastname: Ferrand
authors.affiliation: Université de Franche Comté, UPRES EA 4266 Agents Pathogènes et Inflammation, Besançon, INSERM, CIC 1431, Centre investigation Clinique Biothérapie, Fédération Hospitalo-Universitaire INCREASE, CHRU, CHRU Besançon, Rhumatologie and Université de Franche Comté, Département Universitaire de Thérapeutique, Besançon, France etoussirot@chu-besancon.fr.
authors.forename: Eric
authors.initials: E
authors.lastname: Toussirot
mesh_terms: D018951:Antigens, CD20 / Q000235:genetics* / Q000378:metabolism*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D001402:B-Lymphocytes / Q000378:metabolism / Q000473:pathology; D015415:Biomarkers / Q000378:metabolism; D001706:Biopsy; D016022:Case-Control Studies; D004351:Drug Resistance / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D014644:Genetic Variation / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069283:Rituximab / Q000627:therapeutic use*; D013583:Synovial Membrane / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D018951:Antigens, CD20; D018501:Antirheumatic Agents; D015415:Biomarkers; D000069283:Rituximab